LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Search

Twist Bioscience Corp

Открыт

СекторЗдравоохранение

31.52 -0.44

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

31.2

Макс.

31.7

Ключевые показатели

By Trading Economics

Доход

-48M

-27M

Продажи

3M

99M

Прибыль на акцию

-0.45

Рентабельность продаж

-27.41

Сотрудники

979

EBITDA

-2.3M

-26M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+22.15% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-75M

1.8B

Предыдущая цена открытия

31.96

Предыдущая цена закрытия

31.52

Новостные настроения

By Acuity

50%

50%

168 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

27 нояб. 2025 г., 16:49 UTC

Приобретения, слияния, поглощения

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 нояб. 2025 г., 15:32 UTC

Приобретения, слияния, поглощения

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 нояб. 2025 г., 23:50 UTC

Обсуждения рынка

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 нояб. 2025 г., 23:50 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

27 нояб. 2025 г., 16:05 UTC

Обсуждения рынка

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 нояб. 2025 г., 16:04 UTC

Обсуждения рынка

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 нояб. 2025 г., 15:54 UTC

Приобретения, слияния, поглощения

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 нояб. 2025 г., 15:44 UTC

Приобретения, слияния, поглощения

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 нояб. 2025 г., 15:43 UTC

Приобретения, слияния, поглощения

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 нояб. 2025 г., 15:42 UTC

Приобретения, слияния, поглощения

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 нояб. 2025 г., 15:41 UTC

Приобретения, слияния, поглощения

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 нояб. 2025 г., 15:11 UTC

Обсуждения рынка

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 нояб. 2025 г., 14:26 UTC

Обсуждения рынка

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 нояб. 2025 г., 14:11 UTC

Обсуждения рынка

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 нояб. 2025 г., 14:11 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

27 нояб. 2025 г., 13:35 UTC

Обсуждения рынка

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 нояб. 2025 г., 13:33 UTC

Обсуждения рынка

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 нояб. 2025 г., 13:22 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

27 нояб. 2025 г., 13:22 UTC

Обсуждения рынка

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 нояб. 2025 г., 13:17 UTC

Обсуждения рынка

LVMH Should Be Able to Recover Next Year -- Market Talk

27 нояб. 2025 г., 11:13 UTC

Обсуждения рынка

European Gas Prices Come Under Pressure -- Market Talk

27 нояб. 2025 г., 11:07 UTC

Отчет

Genting: Positive About Prospects Over Longer Term

27 нояб. 2025 г., 11:06 UTC

Отчет

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 нояб. 2025 г., 11:04 UTC

Отчет

Genting: International Travel Demand Expected to Remain Resilient

27 нояб. 2025 г., 11:04 UTC

Отчет

Genting: Global Growth Expected to Remain Subdued

27 нояб. 2025 г., 11:04 UTC

Отчет

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 нояб. 2025 г., 10:59 UTC

Отчет

Genting Bhd 3Q Net Profit Fell 86% on Year

27 нояб. 2025 г., 10:58 UTC

Отчет

Genting Bhd 3Q Rev Rose 14% on Year

27 нояб. 2025 г., 10:56 UTC

Отчет

Genting Bhd 3Q Net MYR30.3M

27 нояб. 2025 г., 10:56 UTC

Отчет

Genting Bhd 3Q EPS MYR0.0079

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

22.15% рост

Прогноз на 12 месяцев

Средняя 38 USD  22.15%

Максимум 42 USD

Минимум 32 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

168 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat